

COMPLETE

Collector: BCH website (Website Survey)
Started: Wednesday, February 12, 2014 8:10:52 AM
Last Modified: Wednesday, February 12, 2014 8:13:41 AM

Time Spent: 00:02:49

PAGE 1

Q1: Type of submission:	Organization

PAGE 2

Q2: Name of the Party:	Respondent skipped this question
Q3: Person submitting this questionnaire:	Respondent skipped this question
Q4: Institution(s) or organization(s) that participated in the testing:	Respondent skipped this question
Q5: Context in which the testing was conducted	Respondent skipped this question
Q6: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. http://bch.cbd.int/database/record.shtml? documentid=104904 and http://bch.cbd.int/database/record.shtml? documentid=104905) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.	Respondent skipped this question
Q7: In what language was the Guidance tested?	Respondent skipped this question

Q8: Name of the other Government:	Respondent skipped this question
Q9: Person submitting this questionnaire:	Respondent skipped this question
Q10: Institution(s) or organization(s) that participated in the testing:	Respondent skipped this question
Q11: Context in which the testing was conducted	Respondent skipped this question
Q12: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. http://bch.cbd.int/database/record.shtml? documentid=104904 and http://bch.cbd.int/database/record.shtml? documentid=104905) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.	Respondent skipped this question
Q13: In what language was the Guidance tested?	Respondent skipped this question

PAGE 4

Q14: Name of the organization:	ENCA EPA interest group On Risk Assessment and Monitoring of Genetically Modified Organisms (GMOs)
Q15: Person submitting this questionnaire:	
Full Name:	Sara Restrepo-Vassalli
Email Address:	sara.restrepo-vassalli@bafu.admin.ch
Q16: Institution(s) or organization(s) that participated in the testing:	Government authority(ies)
Q17: Context in which the testing was conducted	Group event(s) (e.g., workshop, training course, meeting)
Q18: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. http://bch.cbd.int/database/record.shtml?documentid=104904 and http://bch.cbd.int/database/record.shtml?documentid=104905) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.	
Risk Assessment 1:	http://bch.cbd.int/database/results?searchid=592672
Q19: In what language was the Guidance tested?	English

PAGE 5

Q20: Would you like to submit an evaluation of the following section of the Guidance: Part I: The Roadmap for Risk Assessment

Yes

PAGE 6

Q21: This section of the Guidance is practical.1

(no label) Agree

Q22: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:

The paras starting line 398 - to line 417 describe a quite narrow approach for step I. From our perspective there should be no restrictions to RA in advance.

We propose to delete in line 407 "scientifically plausible scenarios". The sentence could possibly read: "In this step, risk assessors develop meaningful risk hypotheses...."

Additionally in line 415 it is proposed to introduce the following changes: "It is important to define a link or pathway between the LMO and a possible adverse effect,

(this proposal is meant to also cover indirect effects and long-term effects which are missing in the proposed approach)

Q23: This section of the Guidance is useful or has utility.2

(no label) Strongly Agree

Q24: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:

Line 229: term "accepted practice". This term is not clear and should be better explained.

Line 235: add: "Reporting of data, source of data and methods...."The whole bullet point starting 235 ff is felt to be very important.

Line 260 ff. "Additional considerations". These bullet points are difficult to understand and would need further explanations.

Altogether the chapter on Overarching issues is very useful and important and is strongly endorsed.

Last para of the chapter on comparators:

Line 369: we propose to quote more precisely: "...please refer to Part II, Section B, of this Guidance."

Q25: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label) Strongly Agree

Q26: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

There is only weak reference to the precautionary approach. In order to ensure better consistency with the Protocol, we would like to propose additional wording for line 293 complementing the last sentence of the para:

"...in order to help applying the precautionary approach in an adequate manner"

The whole para would then read:

"The various forms of uncertainty are considered and described in each step of the risk assessment. In addition, when communicating the results of a risk assessment, it is important to describe, quantitatively or qualitatively, what impact uncertainty may have on the estimated level of risk and on the conclusions and recommendations of the risk assessment in order to help applying the precautionary approach in an adequate manner"

Q27: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label) Strongly Agree

Q28: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q29: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 7

Q30: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LMOs with stacked genes or traits

No

Q31: This section of the Guidance is practical.1	Respondent skipped this question
Q32: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q33: This section of the Guidance is useful or has utility.2	Respondent skipped this question

Q34: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q35: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3	Respondent skipped this question
Q36: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q37: This section of the Guidance takes into account past and present experiences with LMOs.4	Respondent skipped this question
Q38: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q39: Here you may provide further details to explain your answers in evaluating this section of the Guidance:	Respondent skipped this question

PAGE 9

Q40: Would you like to submit an evaluation of the following
section of the Guidance: Part II: Specific types of LMOs or
Traits - Risk assessment of LM crops with tolerance to
abiotic stress

No

41: This section of the Guidance is practical.1	Respondent skipped this question
Q42: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q43: This section of the Guidance is useful or has utility.2	Respondent skipped this question
Q44: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q45: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3	Respondent skipped this question
Q46: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q47: This section of the Guidance takes into account past and present experiences with LMOs.4	Respondent skipped this question

Q48: Would you like to suggest improvements to this section Respondent skipped this question in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: Respondent skipped this question Q49: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

PAGE 11

No Q50: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM mosquitoes

PAGE 12

Q51: This section of the Guidance is practical.1	Respondent skipped this question
Q52: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q53: This section of the Guidance is useful or has utility.2	Respondent skipped this question
Q54: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q55: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3	Respondent skipped this question
Q56: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q57: This section of the Guidance takes into account past and present experiences with LMOs.4	Respondent skipped this question
Q58: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q59: Here you may provide further details to explain your answers in evaluating this section of the Guidance:	Respondent skipped this question

PAGE 13

Q60: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM trees

No

Q61: This section of the Guidance is practical.1 Respondent skipped this question Respondent skipped this question		
to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: Q63: This section of the Guidance is useful or has utility.2 Respondent skipped this question	Q61: This section of the Guidance is practical.1	Respondent skipped this question
Q64: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: Q65: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3 Q66: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: Q67: This section of the Guidance takes into account past and present experiences with LMOs.4 Q68: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: Q69: Here you may provide further details to explain your Respondent skipped this question	to increase its practicality? If so, please indicate the line	Respondent skipped this question
to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: Q65: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3 Q66: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: Q67: This section of the Guidance takes into account past and present experiences with LMOs.4 Q68: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: Q69: Here you may provide further details to explain your Respondent skipped this question Respondent skipped this question	Q63: This section of the Guidance is useful or has utility.2	Respondent skipped this question
Cartagena Protocol on Biosafety.3 Q66: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: Q67: This section of the Guidance takes into account past and present experiences with LMOs.4 Q68: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: Q69: Here you may provide further details to explain your Respondent skipped this question Respondent skipped this question	to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be	Respondent skipped this question
to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: Q67: This section of the Guidance takes into account past and present experiences with LMOs.4 Q68: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: Q69: Here you may provide further details to explain your Respondent skipped this question		Respondent skipped this question
Q68: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: Q69: Here you may provide further details to explain your Respondent skipped this question	to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements	Respondent skipped this question
in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: Q69: Here you may provide further details to explain your Respondent skipped this question	·	Respondent skipped this question
doculor of your may provide farther details to explain your	in order to better take into account past and present experiences with LMOs? If so, please indicate the line	Respondent skipped this question
		Respondent skipped this question

PAGE 15

Q70: Would you like to submit an evaluation of the following
section of the Guidance: Part III: Monitoring of LMOs
Released into the Environment

No

Q71: This section of the Guidance is practical.1	Respondent skipped this question
Q72: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q73: This section of the Guidance is useful or has utility.2	Respondent skipped this question
Q74: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q75: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3	Respondent skipped this question

Q76: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q77: This section of the Guidance takes into account past and present experiences with LMOs.4	Respondent skipped this question
Q78: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:	Respondent skipped this question
Q79: Here you may provide further details to explain your answers in evaluating this section of the Guidance:	Respondent skipped this question

PAGE 17

Q80: Would you like to submit an evaluation of the following section of the Guidance: Background Documents

No

PAGE 18

Q81: This section of the Guidance is practical.1	Respondent skipped this question
Q82: This section of the Guidance is useful or has utility.2	Respondent skipped this question
Q83: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3	Respondent skipped this question
Q84: This section of the Guidance takes into account past and present experiences with LMOs.4	Respondent skipped this question

PAGE 19

Q85: Please use the space below if you wish to provide additional feedback regarding the testing of the Guidance on Risk Assessment of Living Modified Organisms:

Respondent skipped this question